Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting

References

• Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, Phase 1–2 study. Lancet Oncol. 2017;18(8):1061–1075. doi:10.1016/S1470-2045(17)30416-328645776
   PubMed Web of Science ®Google Scholar
• Burnett AK, Hills RK, Nielsen OJ, et al. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial. Leukemia. 2018;32(12):2693–2697. doi:10.1038/s41375-018-0148-329875430
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–407. doi:10.1002/ajh.2500029218851
   PubMed Web of Science ®Google Scholar
• Shahswar R, Hamwi I, Lueck C, et al. Registry for the off-label use of venetoclax in patients with relapsed or refractory acute myeloid leukemia. HemaSphere. 2018;2(Supplement 2):794.
   Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.27895058
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374(4):311–322. doi:10.1056/NEJMoa151325726639348
   PubMed Web of Science ®Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178–184. doi:10.1038/nm.378825599133
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia [J]. Cancer Discov. 2016;6(10):1106–1117. doi:10.1158/2159-8290.CD-16-031327520294
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228. doi:10.1016/S1470-2045(18)30010-X29339097
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi:10.1182/blood-2018-08-86875230361262
   PubMed Web of Science ®Google Scholar
• Bewersdorf JP, Giri S, Wang R. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica. 2020;105(11):2659–2663. doi:10.3324/haematol.2019.24282633131256
   PubMed Web of Science ®Google Scholar
• Goldberg AD, Horvat TZ, Hsu M, et al. Venetoclax combined with either a hypomethylating agent or low-dose cytarabine shows activity in relapsed and refractory myeloid malignancies. Blood. 2017;130(Supplement 1):1353.
   Google Scholar
• Aldoss I, Yang D, Aribi A, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018;103(9):e404–e407. doi:10.3324/haematol.2018.18809429545346
   PubMed Web of Science ®Google Scholar
• Ram R, Amit O, Zuckerman T, et al. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study. Ann Hematol. 2019;98(8):1927–1932. doi:10.1007/s00277-019-03719-631187237
   PubMed Web of Science ®Google Scholar
• Aldoss I, Yang D, Pillai R, et al. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Am J Hematol. 2019;94(10):E253–E255. doi:10.1002/ajh.2556731259427
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Maiti A, Rausch CR, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, Phase 2 trial. Lancet Haematol. 2020;7(10):e724–e736. doi:10.1016/S2352-3026(20)30210-632896301
   PubMed Web of Science ®Google Scholar
• Wang Y-W, Tsai C-H, Lin C-C, et al. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Ann Hematol. 2020;99(3):501–511. doi:10.1007/s00277-020-03911-z31965269
   PubMed Web of Science ®Google Scholar
• Lou Y, Shao L, Mao L, et al. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: a multicenter retrospective study. Leuk Res. 2020;91:106317. doi:10.1016/j.leukres.2020.10631732092584
   PubMed Web of Science ®Google Scholar
• Morsia E, McCullough K, Joshi M, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: mayo Clinic series on 86 patients. Am J Hematol. 2020;95(12):1511–1521. doi:10.1002/ajh.2597832833294
   PubMed Web of Science ®Google Scholar
• Gaut D, Burkenroad A, Duong T, et al. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: a single institution experience. Leuk Res. 2020;90:106314. doi:10.1016/j.leukres.2020.10631432035355
   PubMed Web of Science ®Google Scholar
• Ganzel C, Ram R, Gural A, et al. Venetoclax is safe and efficacious in relapsed/refractory AML. Leuk Lymphoma. 2020;61(9):2221–2225. doi:10.1080/10428194.2020.176196432420775
   PubMed Web of Science ®Google Scholar
• Mali RS, Zhang Q, DeFilippis R, et al. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica. 2020. haematol. 2019;244020.
   Web of Science ®Google Scholar
• Wilde L, Ramanathan S, Kasner M. B-cell lymphoma-2 inhibition and resistance in acute myeloid leukemia. World J Clin Oncol. 2020;11(8):528–540. doi:10.5306/wjco.v11.i8.52832879842
   PubMed Web of Science ®Google Scholar
• Eyre TA, Roeker LE, Fox CP, et al. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. Br J Haematol. 2020;188(6):918–923. doi:10.1111/bjh.1627131682002
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa201297132786187
   PubMed Web of Science ®Google Scholar